Immix Biopharma Eulerpool Uudised

Immix Biopharma Eulerpool News

Immix Biopharma aktsia uudised

Immix Biopharma jälgivad paljud ajakirjanikud ja investorid üle kogu maailma. Kõige värskemad Immix Biopharma uudised paneme siia kokku.

• 3. oktoober ·

  TipRanks
  Immix Biopharma’s Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook
• 2. oktoober ·

  Yahoo
  Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
• 2. oktoober ·

  Thefly.com
  Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
• 19. september ·

  Yahoo
  Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
• 29. august ·

  Yahoo
  Immix Biopharma Independent Director Acquires 2.6% More Stock
• 28. august ·

  Yahoo
  Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
• 28. august ·

  Thefly.com
  Immix Biopharma announces three more sites for NEXICART-2 trial
• 19. august ·

  Yahoo
  What Makes Immix Biopharma (IMMX) a New Buy Stock
• 19. august ·

  TipRanks
  Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)
• 12. august ·

  InvestorPlace
  IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024